Live feed07:00:00·109dPRReleasevia QuantisnowArmata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureusByQuantisnow·Wall Street's wire, on your screen.ARMP· Armata Pharmaceuticals Inc.Health Care
